Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels

Mustafa Naziroǧlu, Bilal Çiǧ, Walter Blum, C. Vízler, Andrea Buhala, Annamária Marton, R. Katona, Katalin Jósvay, Beat Schwaller, Zoltán Oláh, László Pecze

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

There is convincing epidemiological and experimental evidence that capsaicin, a potent natural transient receptor potential cation channel vanilloid member 1 (TRPV1) agonist, has anticancer activity. However, capsaicin cannot be given systemically in large doses, because of its induction of acute pain and neurological inflammation. MRS1477, a dihydropyridine derivative acts as a positive allosteric modulator of TRPV1, if added together with capsaicin, but is ineffective, if given alone. Addition of MRS1477 evoked Ca2+ signals in MCF7 breast cancer cells, but not in primary breast epithelial cells. This indicates that MCF7 cells not only express functional TRPV1 channels, but also produce endogenous TRPV1 agonists. We investigated the effects of MRS1477 and capsaicin on cell viability, caspase-3 and -9 activities and reactive oxygen species production in MCF7 cells. The fraction of apoptotic cells was increased after 3 days incubation with capsaicin (10 μM) paralleled by increased reactive oxygen species production and caspase activity. These effects were even more pronounced, when cells were incubated with MRS1477 (2 μM) either alone or together with CAPS (10 μM). Capsazepine, a TRPV1 blocker, inhibited both the effect of capsaicin and MRS1477. Whole-cell patch clamp recordings revealed that capsaicin-evoked TRPV1-mediated current density levels were increased after 3 days incubation with MRS1477 (2 μM). However, the tumor growth in MCF7 tumor-bearing immunodeficient mice was not significantly decreased after treatment with MRS1477 (10 mg/ kg body weight, i.p., injection twice a week). In conclusion, in view of a putative in vivo treatment with MRS1477 or similar compounds further optimization is required.

Original languageEnglish
Article numbere0179950
JournalPLoS One
Volume12
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Transient Receptor Potential Channels
capsaicin
Capsaicin
breast neoplasms
Modulators
cations
Cells
Breast Neoplasms
receptors
MCF-7 Cells
agonists
cells
reactive oxygen species
Tumors
Reactive Oxygen Species
Bearings (structural)
neoplasms
caspases
caspase-3
neoplasm cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Naziroǧlu, M., Çiǧ, B., Blum, W., Vízler, C., Buhala, A., Marton, A., ... Pecze, L. (2017). Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels. PLoS One, 12(6), [e0179950]. https://doi.org/10.1371/journal.pone.0179950

Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels. / Naziroǧlu, Mustafa; Çiǧ, Bilal; Blum, Walter; Vízler, C.; Buhala, Andrea; Marton, Annamária; Katona, R.; Jósvay, Katalin; Schwaller, Beat; Oláh, Zoltán; Pecze, László.

In: PLoS One, Vol. 12, No. 6, e0179950, 01.06.2017.

Research output: Contribution to journalArticle

Naziroǧlu, M, Çiǧ, B, Blum, W, Vízler, C, Buhala, A, Marton, A, Katona, R, Jósvay, K, Schwaller, B, Oláh, Z & Pecze, L 2017, 'Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels', PLoS One, vol. 12, no. 6, e0179950. https://doi.org/10.1371/journal.pone.0179950
Naziroǧlu, Mustafa ; Çiǧ, Bilal ; Blum, Walter ; Vízler, C. ; Buhala, Andrea ; Marton, Annamária ; Katona, R. ; Jósvay, Katalin ; Schwaller, Beat ; Oláh, Zoltán ; Pecze, László. / Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels. In: PLoS One. 2017 ; Vol. 12, No. 6.
@article{d69b943811884a738fcac6f5fe4a3c64,
title = "Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels",
abstract = "There is convincing epidemiological and experimental evidence that capsaicin, a potent natural transient receptor potential cation channel vanilloid member 1 (TRPV1) agonist, has anticancer activity. However, capsaicin cannot be given systemically in large doses, because of its induction of acute pain and neurological inflammation. MRS1477, a dihydropyridine derivative acts as a positive allosteric modulator of TRPV1, if added together with capsaicin, but is ineffective, if given alone. Addition of MRS1477 evoked Ca2+ signals in MCF7 breast cancer cells, but not in primary breast epithelial cells. This indicates that MCF7 cells not only express functional TRPV1 channels, but also produce endogenous TRPV1 agonists. We investigated the effects of MRS1477 and capsaicin on cell viability, caspase-3 and -9 activities and reactive oxygen species production in MCF7 cells. The fraction of apoptotic cells was increased after 3 days incubation with capsaicin (10 μM) paralleled by increased reactive oxygen species production and caspase activity. These effects were even more pronounced, when cells were incubated with MRS1477 (2 μM) either alone or together with CAPS (10 μM). Capsazepine, a TRPV1 blocker, inhibited both the effect of capsaicin and MRS1477. Whole-cell patch clamp recordings revealed that capsaicin-evoked TRPV1-mediated current density levels were increased after 3 days incubation with MRS1477 (2 μM). However, the tumor growth in MCF7 tumor-bearing immunodeficient mice was not significantly decreased after treatment with MRS1477 (10 mg/ kg body weight, i.p., injection twice a week). In conclusion, in view of a putative in vivo treatment with MRS1477 or similar compounds further optimization is required.",
author = "Mustafa Naziroǧlu and Bilal {\cC}iǧ and Walter Blum and C. V{\'i}zler and Andrea Buhala and Annam{\'a}ria Marton and R. Katona and Katalin J{\'o}svay and Beat Schwaller and Zolt{\'a}n Ol{\'a}h and L{\'a}szl{\'o} Pecze",
year = "2017",
month = "6",
day = "1",
doi = "10.1371/journal.pone.0179950",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Targeting breast cancer cells by MRS1477, a positive allosteric modulator of TRPV1 channels

AU - Naziroǧlu, Mustafa

AU - Çiǧ, Bilal

AU - Blum, Walter

AU - Vízler, C.

AU - Buhala, Andrea

AU - Marton, Annamária

AU - Katona, R.

AU - Jósvay, Katalin

AU - Schwaller, Beat

AU - Oláh, Zoltán

AU - Pecze, László

PY - 2017/6/1

Y1 - 2017/6/1

N2 - There is convincing epidemiological and experimental evidence that capsaicin, a potent natural transient receptor potential cation channel vanilloid member 1 (TRPV1) agonist, has anticancer activity. However, capsaicin cannot be given systemically in large doses, because of its induction of acute pain and neurological inflammation. MRS1477, a dihydropyridine derivative acts as a positive allosteric modulator of TRPV1, if added together with capsaicin, but is ineffective, if given alone. Addition of MRS1477 evoked Ca2+ signals in MCF7 breast cancer cells, but not in primary breast epithelial cells. This indicates that MCF7 cells not only express functional TRPV1 channels, but also produce endogenous TRPV1 agonists. We investigated the effects of MRS1477 and capsaicin on cell viability, caspase-3 and -9 activities and reactive oxygen species production in MCF7 cells. The fraction of apoptotic cells was increased after 3 days incubation with capsaicin (10 μM) paralleled by increased reactive oxygen species production and caspase activity. These effects were even more pronounced, when cells were incubated with MRS1477 (2 μM) either alone or together with CAPS (10 μM). Capsazepine, a TRPV1 blocker, inhibited both the effect of capsaicin and MRS1477. Whole-cell patch clamp recordings revealed that capsaicin-evoked TRPV1-mediated current density levels were increased after 3 days incubation with MRS1477 (2 μM). However, the tumor growth in MCF7 tumor-bearing immunodeficient mice was not significantly decreased after treatment with MRS1477 (10 mg/ kg body weight, i.p., injection twice a week). In conclusion, in view of a putative in vivo treatment with MRS1477 or similar compounds further optimization is required.

AB - There is convincing epidemiological and experimental evidence that capsaicin, a potent natural transient receptor potential cation channel vanilloid member 1 (TRPV1) agonist, has anticancer activity. However, capsaicin cannot be given systemically in large doses, because of its induction of acute pain and neurological inflammation. MRS1477, a dihydropyridine derivative acts as a positive allosteric modulator of TRPV1, if added together with capsaicin, but is ineffective, if given alone. Addition of MRS1477 evoked Ca2+ signals in MCF7 breast cancer cells, but not in primary breast epithelial cells. This indicates that MCF7 cells not only express functional TRPV1 channels, but also produce endogenous TRPV1 agonists. We investigated the effects of MRS1477 and capsaicin on cell viability, caspase-3 and -9 activities and reactive oxygen species production in MCF7 cells. The fraction of apoptotic cells was increased after 3 days incubation with capsaicin (10 μM) paralleled by increased reactive oxygen species production and caspase activity. These effects were even more pronounced, when cells were incubated with MRS1477 (2 μM) either alone or together with CAPS (10 μM). Capsazepine, a TRPV1 blocker, inhibited both the effect of capsaicin and MRS1477. Whole-cell patch clamp recordings revealed that capsaicin-evoked TRPV1-mediated current density levels were increased after 3 days incubation with MRS1477 (2 μM). However, the tumor growth in MCF7 tumor-bearing immunodeficient mice was not significantly decreased after treatment with MRS1477 (10 mg/ kg body weight, i.p., injection twice a week). In conclusion, in view of a putative in vivo treatment with MRS1477 or similar compounds further optimization is required.

UR - http://www.scopus.com/inward/record.url?scp=85021247219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021247219&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0179950

DO - 10.1371/journal.pone.0179950

M3 - Article

C2 - 28640864

AN - SCOPUS:85021247219

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e0179950

ER -